Non-small Cell Lung Cancer
A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer
The main purpose of this study is to evaluate the safety of the study drug ramucirumab in combination with weekly docetaxel in participants with stage IV non-small cell lung cancer (NSCLC) following disease progression after prior platinum-based chemotherapy.
This trial stopped recruiting or enrolling participants prematurely and will not start again. We are no longer examining or treating participants. The trial may have been stopped for many reasons. You may contact Lilly for further information.
Your participation may continue for as long as you and your study doctor feel that you are benefiting from the study treatment.
Here you can find out a bit more about the requirements for volunteers who took part in this study
- Participant must have confirmed non-small cell lung cancer (NSCLC) diagnosis by histology or cytology and have disease progression on or after prior platinum-based chemotherapy regimen for locally advanced or metastatic NSCLC; prior immunotherapy for NSCLC is allowed
- Male participant must be sterile or agree to use a highly effective method of contraception (2 methods preferred), and agree not to donate sperm during the study and for at least 6 months following the last dose of study treatment
- Female participant must be surgically sterile, postmenopausal, or agree to use a highly effective method of contraception (2 methods preferred) during the study and for 6 months following the last dose of study treatment
- Female participant of childbearing potential must have a negative serum or urine pregnancy test
- Participant must not have prior therapy with docetaxel or ramucirumab
- Participant tumor must not contain small cell lung cancer
- Participant must not have had a bowel obstruction, extensive intestinal resection, Crohn's disease, ulcerative colitis, or chronic diarrhea
- Participant must not have an elective or a planned major surgery during the course of the trial
- Participant must not be receiving current treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, chemoembolization, or targeted therapy
- Participant must not be receiving chronic therapy with nonsteroidal anti-inflammatory drugs (NSAIDs); for example, indomethacin, ibuprofen, naproxen, or similar agents) or other antiplatelet agents (for example, clopidogrel, ticlopidine, dipyridamole, and anagrelide). Aspirin use at doses up to 325 milligrams/day is permitted